価格表

在庫・価格 : 2025年09月14日 09時02分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-SARS-CoV-2 (COVID-19) Spike, Rabbit-Poly
データシート
GTX135356 GNTジーンテックス
GeneTex International Corporation
25 μl ¥30,000
(未発注)
追加

在庫・価格 : 2025年09月14日 09時02分 現在

Anti-SARS-CoV-2 (COVID-19) Spike, Rabbit-Poly

  • 商品コード:GTX135356
  • メーカー:GNT
  • 包装:25μl
  • 価格: ¥30,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Garc鱈a-Arriaza J et al. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. J Virol 2021 Jan;
Garc鱈a-Arriaza J et al
2021/01/01
PubMed
2 Sukhikh G et al., Sukhikh G, Viruses, 2021

PubMed
3 . Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol 2021 05;6(59)

2021/01/01
PubMed
4 Sukhikh G et al. Vertical Transmission of SARS-CoV-2 in Second Trimester Associated with Severe Neonatal Pathology. Viruses 2021 03;13(3)
Sukhikh G et al
2021/01/01
PubMed
5 Harbour JC et al. Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein. J Immunol 2021 06;206(11):2596-2604
Harbour JC et al
2021/01/01
PubMed
6 Yang B et al. SNX27 suppresses SARS-CoV-2 infection by inhibiting viral lysosome/late endosome entry. Proc Natl Acad Sci U S A 2022 01;119(4)
Yang B et al
2022/01/01
PubMed
7 Huang HC et al. Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. EBioMedicine 2021 Dec;74:103712
Huang HC et al
2021/01/01
PubMed
8 Ordonez AA et al. Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice. Commun Biol 2022 Mar;5(1):242
Ordonez AA et al
2022/01/01
PubMed
9 Meseda CA et al. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge. NPJ Vaccines 2021 Dec;6(1):145
Meseda CA et al
2021/01/01
PubMed
10 Lin WS et al. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. Front Immunol 2021;12:795741
Lin WS et al
2021/01/01
PubMed
11 Hsieh MH et al. Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles. Front Immunol 2021;12:641360
Hsieh MH et al
2021/01/01
PubMed
12 Routhu NK et al. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Immunity 2021 Mar;54(3):542-556.e9
Routhu NK et al
2021/01/01
PubMed
13 V叩squez V et al. SARS-CoV-2 electrochemical immunosensor based on the spike-ACE2 complex. Anal Chim Acta 2022 May;1205:339718
V叩squez V et al
2022/01/01
PubMed
14 Zeng W et al. Evidence of Infection of Human Embryonic Stem Cells by SARS-CoV-2. Front Cell Infect Microbiol 2022;12:911313
Zeng W et al
2022/01/01
PubMed
15 Cheedarla N et al. Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers. iScience 2023 Nov;26(11):108256
Cheedarla N et al
2023/01/01
PubMed
16 Park SB et al. SARS-CoV-2 omicron variants harbor spike protein mutations responsible for their attenuated fusogenic phenotype. Commun Biol 2023 May;6(1):556
Park SB et al
2023/01/01
PubMed
17 Hayashi H et al. Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. Sci Rep 2022 Dec;12(1):20923
Hayashi H et al
2022/01/01
PubMed
18 Prout A et al. Functional profiling of Covid 19 vaccine candidate by flow virometry. Vaccine 2022 Sep;40(37):5529-5536
Prout A et al
2022/01/01
PubMed
19 Gao SY et al. Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern. Front Immunol 2022;13:1038562
Gao SY et al
2022/01/01
PubMed
20 Arai Y et al. Stimulation of interferon-β responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists. iScience 2023 Jan;26(1):105742
Arai Y et al
2023/01/01
PubMed
21 Ruiz MJ et al. Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis. Front Immunol 2022;13:842468
Ruiz MJ et al
2022/01/01
PubMed
22 Kumar CS et al. Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells. ACS Infect Dis 2022 Oct;8(10):2119-2132
Kumar CS et al
2022/01/01
PubMed
23 Vakhrusheva AV et al. SARS-CoV-2 Subunit Virus-like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study. Vaccines (Basel) 2022 Aug;10(8)
Vakhrusheva AV et al
2022/01/01
PubMed
24 Merino VF et al. Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells. Antiviral Res 2023 Mar;211:105550
Merino VF et al
2023/01/01
PubMed
25 Imanishi I et al. Guest edited collection serological study of SARS-CoV-2 antibodies in japanese cats using protein-A/G-based ELISA. BMC Vet Res 2022 Dec;18(1):443
Imanishi I et al
2022/01/01
PubMed
26 Park H et al. TMED3 Complex Mediates ER Stress-Associated Secretion of CFTR, Pendrin, and SARS-CoV-2 Spike. Adv Sci (Weinh) 2022 Aug;9(24):e2105320
Park H et al
2022/01/01
PubMed
27 Ishigaki H et al. An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic m
Ishigaki H et al
2022/01/01
PubMed
28 Gellenoncourt S et al. The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. J Virol 2022 Oct;96(19):e0130122
Gellenoncourt S et al
2022/01/01
PubMed
  • No.: 1
  • 文献情報:
    Garc鱈a-Arriaza J et al. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. J Virol 2021 Jan;
    Garc鱈a-Arriaza J et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Sukhikh G et al., Sukhikh G, Viruses, 2021

  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    . Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol 2021 05;6(59)

    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Sukhikh G et al. Vertical Transmission of SARS-CoV-2 in Second Trimester Associated with Severe Neonatal Pathology. Viruses 2021 03;13(3)
    Sukhikh G et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Harbour JC et al. Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein. J Immunol 2021 06;206(11):2596-2604
    Harbour JC et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Yang B et al. SNX27 suppresses SARS-CoV-2 infection by inhibiting viral lysosome/late endosome entry. Proc Natl Acad Sci U S A 2022 01;119(4)
    Yang B et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Huang HC et al. Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. EBioMedicine 2021 Dec;74:103712
    Huang HC et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Ordonez AA et al. Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice. Commun Biol 2022 Mar;5(1):242
    Ordonez AA et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Meseda CA et al. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge. NPJ Vaccines 2021 Dec;6(1):145
    Meseda CA et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Lin WS et al. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. Front Immunol 2021;12:795741
    Lin WS et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Hsieh MH et al. Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles. Front Immunol 2021;12:641360
    Hsieh MH et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Routhu NK et al. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Immunity 2021 Mar;54(3):542-556.e9
    Routhu NK et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    V叩squez V et al. SARS-CoV-2 electrochemical immunosensor based on the spike-ACE2 complex. Anal Chim Acta 2022 May;1205:339718
    V叩squez V et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Zeng W et al. Evidence of Infection of Human Embryonic Stem Cells by SARS-CoV-2. Front Cell Infect Microbiol 2022;12:911313
    Zeng W et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Cheedarla N et al. Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers. iScience 2023 Nov;26(11):108256
    Cheedarla N et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Park SB et al. SARS-CoV-2 omicron variants harbor spike protein mutations responsible for their attenuated fusogenic phenotype. Commun Biol 2023 May;6(1):556
    Park SB et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Hayashi H et al. Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. Sci Rep 2022 Dec;12(1):20923
    Hayashi H et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Prout A et al. Functional profiling of Covid 19 vaccine candidate by flow virometry. Vaccine 2022 Sep;40(37):5529-5536
    Prout A et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Gao SY et al. Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern. Front Immunol 2022;13:1038562
    Gao SY et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Arai Y et al. Stimulation of interferon-β responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists. iScience 2023 Jan;26(1):105742
    Arai Y et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Ruiz MJ et al. Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis. Front Immunol 2022;13:842468
    Ruiz MJ et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Kumar CS et al. Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells. ACS Infect Dis 2022 Oct;8(10):2119-2132
    Kumar CS et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Vakhrusheva AV et al. SARS-CoV-2 Subunit Virus-like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study. Vaccines (Basel) 2022 Aug;10(8)
    Vakhrusheva AV et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Merino VF et al. Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells. Antiviral Res 2023 Mar;211:105550
    Merino VF et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Imanishi I et al. Guest edited collection serological study of SARS-CoV-2 antibodies in japanese cats using protein-A/G-based ELISA. BMC Vet Res 2022 Dec;18(1):443
    Imanishi I et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Park H et al. TMED3 Complex Mediates ER Stress-Associated Secretion of CFTR, Pendrin, and SARS-CoV-2 Spike. Adv Sci (Weinh) 2022 Aug;9(24):e2105320
    Park H et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Ishigaki H et al. An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic m
    Ishigaki H et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Gellenoncourt S et al. The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. J Virol 2022 Oct;96(19):e0130122
    Gellenoncourt S et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed